Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 26 to 50 of 2524

TitleReference numberPublishedLast updated
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Suspected sepsis in over 16sQS213
Intrapartum careNG235
Low-energy contact X-ray brachytherapy for rectal cancerIPG809
Fetal monitoring in labourNG229
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
VA ECMO for severe acute heart failure in adultsIPG807
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestIPG808
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Head injuryQS74
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessmentHTG760
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
HIV testing: increasing uptake among people who may have undiagnosed HIVNG60
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098

Results per page

  1. 10
  2. 25
  3. 50
  4. All